Comprehensive imaging and quantification of blood flow for investigating ocular diseases without additional contrast agent

无需额外造影剂即可对血流进行全面成像和量化以研究眼部疾病

基本信息

批准号：
10295545
负责人：
Mircea Mujat
金额：
$ 67.83万
依托单位：
PHYSICAL SCIENCES, INC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2023-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10295545
关键词：
3-Dimensional Address Age related macular degeneration Animal Model Animals Area Biological Markers Blindness Blood Vessels Blood Volume Blood flow Caliber Choroid Clinic Clinical Clinical Engineering Clinical Research Collaborations Contrast Media Coupled Data Detection Development Diabetic Retinopathy Diagnostic Imaging Disease Ensure Evaluation Eye Eye diseases Feasibility Studies Flowmetry Fostering Foundations Funding Future Glaucoma Human Volunteers Image Imaging Device Imaging technology Individual Institutional Review Boards Knowledge Laboratory Research Location Maps Measurable Measurement Microgravity Monitor Morphology Multimodal Imaging New York Ophthalmologist Ophthalmology Optical Coherence Tomography Outcome Patients Pattern Phase Positioning Attribute Protocols documentation Recording of previous events Research Resolution Retina Retinal Degeneration Retinal Diseases Risk Rodent Rodent Diseases Rodent Model Scanning Scientist Severity of illness Structure System Techniques Technology Testing Thick Translations United States National Aeronautics and Space Administration Universities Vision Visualization base blood flow measurement clinical practice commercialization density design experience hemodynamics human subject imager imaging approach imaging modality imaging platform imaging program imaging study imaging system improved in vivo instrument instrumentation medical schools multimodality neurovascular new technology novel novel diagnostics patient population physical science programs prototype recruit research and development retinal imaging three dimensional structure

项目摘要

Project Summary/Abstract Physical Sciences Inc. (PSI) in collaboration with New York University (NYU) School of Medicine proposes to develop a novel ophthalmic imaging platform for characterizing retinal morphology and monitoring ocular blood flow abnormalities. This platform will combine non-invasive measurements of retina/choroid structure and ocular blood flow based on optical coherence tomography (OCT) and wide- field semi-quantitative global flow visualization using line-scanning Doppler flowmetry (LSDF). The combination of these two imaging modalities within the same imaging platform enables comprehensive assessment of blood flow in the retina and choroid. This novel imaging platform will enable imaging studies in animals and human subjects with normal vision or with various retinal diseases. Prior PSI experience in developing advanced ophthalmic imaging systems coupled with our collaborators' expertise in Ophthalmology will be leveraged to ensure the successful outcome of this important R&D program. A feasibility study will be performed during the Phase I program by imaging normal and diseased rodent models using a benchtop instrument. A clinical prototype instrument will be manufactured and tested clinically in Phase II in the NYU population of patients to highlight hemodynamic retinal biomarkers. We choose to focus on diseases that are the leading causes of blindness including, age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma to demonstrate the clinical utility of our novel system. We will recruit healthy individuals to set a reference, and subjects with AMD, DR, and glaucoma at a wide range of disease severity. In all of these conditions, the ability to record in vivo blood flow will provide novel information that will open new diagnostic and treatment avenues.

项目概要/摘要物理科学公司 (PSI) 与纽约大学 (NYU) 医学院合作提议开发一种新型眼科成像平台来表征视网膜形态和监测眼部血流异常。该平台将结合非侵入式测量基于光学相干断层扫描 (OCT) 和广角的视网膜/脉络膜结构和眼部血流使用线扫描多普勒血流计（LSDF）进行现场半定量全局血流可视化。这将这两种成像方式组合在同一成像平台内可以实现全面的成像评估视网膜和脉络膜的血流量。这种新颖的成像平台将使成像成为可能对视力正常或患有各种视网膜疾病的动物和人类受试者进行研究。之前的 PSI 开发先进眼科成像系统的经验加上我们合作者的专业知识将利用眼科博士学位来确保这一重要研发计划的成功结果。在第一阶段计划期间，将通过正常和患病啮齿动物的成像进行可行性研究使用台式仪器的模型。将制造并测试临床原型仪器在纽约大学患者群体中进行第二阶段临床研究，以突出血流动力学视网膜生物标志物。我们选择关注导致失明的主要原因的疾病，包括与年龄相关的黄斑病变变性（AMD）、糖尿病性视网膜病变（DR）和青光眼，以证明我们的新型药物的临床实用性系统。我们将招募健康个体来设定参考，并招募患有 AMD、DR 和青光眼的受试者疾病严重程度范围广泛。在所有这些条件下，记录体内血流的能力将提供新的信息，将开辟新的诊断和治疗途径。